Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trialClaudia M. Denkinger, Michael Schmitt, Lukas Baumann et al.|Nature Cancer|2022Cited by 62
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialClaudia M. Denkinger, Michaël Schmitt, Maike Janssen et al.|medRxiv|2022Cited by 4
S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSIONC. Müller-Tidow, Claudia M. Denkinger, Maike Janssen et al.|HemaSphere|2022Cited by 2
1142. Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trialClaudia M. Denkinger, Carsten Müller‐Tidow, Maike Janssen et al.|Open Forum Infectious Diseases|2022Cited by 0